simfo GmbH is a research and development facility with advanced expertise in personalized medicine, based in Bayreuth, Germany. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics in order to optimize personalized therapy. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. This allows more rapid intervention options and therefore better treatment. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development. Stratification of the patients by means of the maintrac® platform makes it possible to effectively distinguish responders from non-responders.